The Motley Fool

Top brokers name 3 ASX shares to sell today

On Wednesday I looked at a few shares that have recently found favour with brokers and been given buy ratings.

Unfortunately, not all shares on the market are in favour with brokers right now. Three which have been given sell ratings are listed below. Here’s why brokers think you should avoid them:

Australian Pharmaceutical Industries Ltd (ASX: API)

According to a note out of Credit Suisse, it has downgraded this pharmacy chain operator and supplier’s shares to an underperform rating from neutral with a lowered price target of $1.55. The broker believes that the company’s shares could come under pressure next month when its reports its latest results. Credit Suisse appears to think that investors have become too focused on its Clearskincare acquisition and lost focus on the challenging operating environment its core business is facing. I agree with Credit Suisse on Australian Pharmaceutical Industries and think investors ought to stay clear of its shares until they have seen its results.

Independence Group NL (ASX: IGO)

A note out of the Macquarie equities desk reveals that its analysts have downgraded the miner’s shares to an underperform rating from neutral and cut the price target on them to $4.20. According to the note, the broker has made the move after adjusting its nickel price forecasts. This has led to a significant cut to its earnings forecasts for Independence Group this year. I’m sitting on the fence with independence Group and would class it as a hold at these levels.

Nufarm Limited (ASX: NUF)

Analysts at Deutsche Bank have retained their sell rating and cut the price target on this crop protection company’s shares to $6.10 following the release of a weaker than expected full year result on Wednesday. According to the note, the broker appears concerned by numerous risks that Nufarm faces such as drought, higher input costs, and U.S. tariffs. I agree with Deutsche and would avoid Nufarm’s shares after that result. I don’t believe its shares are trading at a level that offers a sufficient risk/reward.

While the shares above may be the ones to sell, this hot stock is the one to buy right now if you ask me.

Top Australian Stock Picker Just Issued Rare “Double Down” Buy Alert

Discover why this legendary Australian stock-picker just issued a “Double Down” buy alert to his exclusive group of insiders… and why he’s convinced this might be the single most attractive entry point for years to come.

Simply click here to get started and access our secure sign-up page.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here’s the best part: we think there’s one ASX stock that’s uniquely positioned to profit immensely from this explosive new industry… taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more